Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14601593 | 0.85 | NAMPT (0.46) | NAMPTMTNR1AMTNR1BCNR1DRD2 | |
| SCHEMBL3964266 | 0.84 | NAMPT (0.38) | NAMPTMTNR1AMTNR1BCNR1ESR1 | |
| SCHEMBL3970340 | 0.84 | NAMPT (0.38) | NAMPTMTNR1AMTNR1BCNR1ESR1 | |
| SCHEMBL14091686 | 0.84 | NAMPT (0.38) | NAMPTMTNR1AMTNR1BCNR1ESR1 | |
| SCHEMBL3970338 | 0.84 | NAMPT (0.38) | NAMPTMTNR1AMTNR1BCNR1ESR1 | |
| SCHEMBL3965006 | 0.82 | NPC1 (0.42) | NAMPTCNR1ESR2KMT2ADRD2 | |
| SCHEMBL3965551 | 0.79 | ESR1 (0.36) | NAMPTESR1ESR2KMT2ADRD2 | |
| SCHEMBL14115859 | 0.79 | NAMPT (0.40) | NAMPTMTNR1AMTNR1BCNR1KMT2A | |
| SCHEMBL3968226 | 0.79 | ESR1 (0.36) | NAMPTMTNR1AMTNR1BESR1ESR2 | |
| SCHEMBL3968222 | 0.79 | ESR1 (0.36) | NAMPTMTNR1AMTNR1BESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | HTR2C, HTR2A, HTR1A | NAMPT 4818/4885MTNR1A 213/4885MTNR1B 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.